Learning the pace
Phase 1 and 2 · 2018–2020 publications
What if enthusiasm moves faster than tolerability?
Subject One is keen to race ahead. His stomach has submitted a competing proposal. Doctide points to a protocol, not a stopwatch. “Enthusiasm is not a measurement.” Subject One adds a new column to his notebook: things worth reporting.
What changes here
Early studies helped researchers understand tolerability and refine escalation protocols. Feeling unwell was not proof of success. [3]
Read the study details & dates
Early human testing
The discovery program reported Phase 1/1b work involving 142 people, including healthy volunteers and people with type 2 diabetes, across study treatments and comparators. Researchers examined tolerability, exposure and early metabolic signals; gastrointestinal effects were dose-related. [1]
A longer Phase 2 comparison
A 26-week randomized trial in type 2 diabetes compared tirzepatide with placebo and dulaglutide. Glucose, weight and tolerability findings informed further development. [2]
The protocol learns to proceed more gradually
An escalation study found that lower starting doses and smaller increments appeared to improve tolerability. This was a protocol finding, not a suggestion that patients design their own regimen. [3]
What this does not establish
The stomach remark is fictional, not a documented event in one participant. Feeling unwell is not proof that a drug is working, and the historical protocols are not dosing instructions.
Original sources
- Phase 1/1b within the discovery publication
- Phase 2 tirzepatide trial (2018)
- Dose-escalation tolerability study (2020)
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story